Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07484074 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324
A Phase 1 study of Diabetic Macular Edema (DME) and Neovascular (Wet) Age-Related Macular Degeneration, sponsored by Ollin Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 164
- Enrollment target
- 20
- Study locations
NCT07484074 is a Phase 1 study of Diabetic Macular Edema (DME) and Neovascular (Wet) Age-Related Macular Degeneration that has completed, run by Ollin Biosciences. The registered enrollment target is 164 participants, below the 341-participant average among 8 other Diabetic Macular Edema (DME) trials with a reported enrollment target (52% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT07484074, a Phase 1 study of Diabetic Macular Edema (DME) and Neovascular (Wet) Age-Related Macular Degeneration, has completed, sponsored by Ollin Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 164 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324
Conditions Studied
Interventions
- DRUG Faricimab
- DRUG OLN324
Study Locations (20)
California
- Glendale, CA - Glendale
- Pasadena, CA - Pasadena
- Sacramento, CA - Sacramento
- Walnut Creek, CA - Walnut Creek
Florida
- Fort Myers, FL - Fort Myers
- Saint Petersburg, FL - St. Petersburg
- Winter Haven, FL - Winter Haven
Texas
- Abilene, TX - Abilene
- Arlington, TX - Arlington
- Austin, TX - Austin
Arizona
- Phoenix, AZ - Phoenix
Connecticut
- Waterford, CT - Waterford
Illinois
- Oak Forest, IL - Oak Forest
Maryland
- Hagerstown, MD - Hagerstown
Michigan
- Grand Rapids, MI - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2025-02-12 |
| Est. Completion | 2025-12-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07484074
The ClinicalTrials.gov registry entry for NCT07484074 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 341-participant average among 8 other Diabetic Macular Edema (DME) trials with a reported enrollment target (52% lower). The listed sponsor is Ollin Biosciences, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetic Macular Edema (DME) appearing as the primary indexed condition, and to 2 interventions - of which Faricimab is the first listed.
NCT07484074 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT07484074 about?
NCT07484074 is a clinical study titled "A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324". A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324
What is the current status of trial NCT07484074?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 164 participants. The study started on 2025-02-12. Estimated completion is 2025-12-09.
What conditions does trial NCT07484074 study?
This clinical trial studies the following conditions: Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration.
What interventions are being tested in trial NCT07484074?
The interventions under investigation include: Faricimab (DRUG), OLN324 (DRUG).
Who is sponsoring clinical trial NCT07484074?
This trial is sponsored by Ollin Biosciences, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07484074 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema (DME)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Avoralstat In Participants With Diabetic Macular Edema
RECRUITING · Phase 1
-
A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 1
-
High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy
RECRUITING · Phase 4
-
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
RECRUITING · Phase 3
-
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
RECRUITING · Phase 3
-
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Diabetic Macular Edema (DME)
All registered trials for this condition
Neovascular (Wet) Age-Related Macular Degeneration
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.